Summary

In this episode, Dr. Farah Kamangar and Dr. Tina Bhutani discuss the efficacy and safety of Tapinarof, a non-steroidal topical therapy for psoriasis and atopic dermatitis. They highlight the impressive results of clinical trials, with 35-40% of psoriasis patients achieving clear or almost clear skin after 12 weeks of treatment. They also discuss the potential benefits of Tupinarof for atopic dermatitis patients. The side effects of folliculitis and headaches are mentioned, but overall, patients tolerate the medication well. The episode concludes with a discussion on the future of Tapinarof, including potential pediatric indications.

This episode is sponsored by an educational grant from the company Dermavant.

Takeaways

• Tapinarof is a non-steroidal topical therapy that has shown impressive efficacy in treating psoriasis, with 35-40% of patients achieving clear or almost clear skin after 12 weeks of treatment.